Stock CANF CAN-FITE BIOPHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Pharmaceuticals

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 10:24:55 2024-04-30 am EDT 		5-day change 1st Jan Change
2.6 ILa 0.00% Intraday chart for Can-Fite BioPharma Ltd. 0.00% 0.00%
Apr. 03 Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study CI
Mar. 28 Can-Fite Biopharma Ltd. Announces Clinical Update CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 12.97 28.72 38.62 19.52 8.817 10.43 - -
Enterprise Value (EV) 1 12.97 28.72 19.48 19.52 8.817 10.43 10.43 10.43
P/E ratio -0.95 x -1.49 x -1.52 x -2.35 x -0.71 x - - -
Yield - - - - - - - -
Capitalization / Revenue 6.38 x 37.6 x 45.3 x 24.1 x 11.9 x 13 x 13 x 13 x
EV / Revenue 6.38 x 37.6 x 45.3 x 24.1 x 11.9 x 13 x 13 x 13 x
EV / EBITDA - - - - - - - -
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 119,656 463,769 815,746 815,746 1,224,837 1,497,128 - -
Reference price 2 0.3740 0.1990 0.1470 0.0840 0.0260 0.0260 0.0260 0.0260
Announcement Date 3/27/20 3/25/21 3/24/22 3/30/23 3/28/24 - - -
1ILS in Million2ILS
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2.032 0.763 0.853 0.81 0.743 0.8 0.8 0.8
EBITDA - - - - - - - -
EBIT 1 -12 -14.14 -12.84 -10.1 -8.195 -7.05 -7.6 -8.725
Operating Margin -590.7% -1,853.08% -1,505.51% -1,246.42% -1,102.96% -881.25% -950% -1,090.62%
Earnings before Tax (EBT) 1 -9.587 -14.44 -12.62 -10.17 -7.634 -0.3 - -
Net income 1 -9.587 -14.44 -12.62 -10.17 -7.634 -6.65 -7.2 -8.325
Net margin -471.8% -1,892.92% -1,478.9% -1,255.93% -1,027.46% -831.25% -900% -1,040.62%
EPS 2 -0.3942 -0.1332 -0.0967 -0.0358 -0.0367 - - -
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/27/20 3/25/21 3/24/22 3/30/23 3/28/24 - - -
1USD in Million2ILS
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4
Net sales 1 0.251 0.204 0.205 0.204 0.204 0.197 0.196 0.196 0.196 0.155
EBITDA - - - - - - - - - -
EBIT 1 -3.51 -4.028 -2.37 -2.07 -2.573 -3.083 - -1.784 -1.865 -1.834
Operating Margin -1,398.41% -1,974.51% -1,156.1% -1,014.71% -1,261.27% -1,564.97% - -910.2% -951.53% -1,183.23%
Earnings before Tax (EBT) 1 -3.4 -4.118 -2.434 -2.191 -2.529 -3.019 - -1.67 -1.762 -1.652
Net income 1 -3.4 -4.118 -2.434 -2.191 -2.529 -3.019 - -1.67 -1.762 -1.652
Net margin -1,354.58% -2,018.63% -1,187.32% -1,074.02% -1,239.71% -1,532.49% - -852.04% -898.98% -1,065.81%
EPS 2 -0.0319 -0.0322 - - -0.0342 - - - - -0.0367
Dividend per Share - - - - - - - - - -
Announcement Date 11/26/21 3/24/22 5/26/22 8/25/22 11/25/22 3/30/23 6/1/23 8/31/23 11/30/23 3/28/24
1USD in Million2ILS
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - 19.1 - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - - 0.01 - - - - -
Capex / Sales - - 1.29% - - - - -
Announcement Date 3/27/20 3/25/21 3/24/22 3/30/23 3/28/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Can-Fite BioPharma Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.026
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CAN-FITE BIOPHARMA LTD. Stock Can-Fite BioPharma Ltd.
0.00% 10.36M
CSL LIMITED Stock CSL Limited
-3.45% 87.17B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.1B
BIOGEN INC. Stock Biogen Inc.
-16.98% 31.38B
UCB Stock UCB
+57.86% 25.12B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.24% 15.59B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 12B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.8B
INCYTE CORPORATION Stock Incyte Corporation
-17.10% 11.8B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.89% 8.81B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. CANF Stock
  4. Financials Can-Fite BioPharma Ltd.